Evvy raises $40 million to bring AI diagnostics to fertility

Evvy, officially Allora Health Inc., frames its work around a data gap its co-founder and CEO Priyanka Jain traces back to clinical trials of new drugs generally excluding women until 1993. That leaves only about 30 years of research data on female biology, which Jain says helps explain misdiagnosis rates higher than 50% for some conditions and a recurrence rate of common vaginal symptoms above 60%. The company says it has spent more than five years building what Jain calls the world's largest clinical-grade dataset on the vaginal microbiome and women's health outcomes, and it has already identified six distinct bacterial vaginosis subtypes that it says support more personalized treatment pathways.

Catalio Capital Managing Partner Jacob Vogelstein said he was drawn to Evvy by the combination of proprietary data, clinical evidence and a growing biomarker discovery engine. That rationale points to why the round matters beyond the dollar figure: the investors are betting that a dataset tied to clinical outcomes, rather than a general-purpose AI model, is the durable asset in women's health.

The next test is fertility. Jain describes the vaginal microbiome as an important and actionable biological signal but not the only one, since fertility involves a much larger biological system. Whether Evvy's approach generalizes from vaginal health to that broader problem will depend on data the company says it will share later this year, and on whether clinicians adopt its interpretations inside a fertility patient's wider care plan.